Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA lifted the clinical hold on ARD-101’s Investigational New Drug application.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA lifted the clinical hold on ARD-101’s Investigational New Drug application
- Regulatory clearance enables clinical development for hyperphagia in Prader-Willi Syndrome
- Investor conference call scheduled for October 23, 2026 at 8:00 a.m. ET
- Exhibit 99.1 contains the company’s full announcement
Item EX-99.1 · Exhibit EX-99.1
- FDA lifted the clinical hold on ARD-101, reopening a path for Prader-Willi Syndrome development
- Prior hold followed reversible ECG changes, creating a key cardiac-safety overhang for investors
- No cardiac events observed at 200 mg and 400 mg twice-daily doses in the additional ECG study
- Phase 3 resumption still depends on FDA alignment regarding trial design, with possible additional studies
- October 23 webcast will review unblinded HERO and OLE data, though both trials terminated early and were not efficacy-powered
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.